Genistein (4) acts through different pathways as a PTK (protein tyrosine kinase) inhibitor against breast cancer cells (Peterson and Barnes, 1996) and causes upregulation of E-Cadherin in MOLT4 (human acute T lymphoblastic leukaemia), JURKAT (human immortalized T cell leukemia), and ALL (acute lymphoblastic leukemia) cell lines (Namordizadeh, 2019). Here, PTK2B is linked to breast cancer.